A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/04/2011	US8029808 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
10/04/2011	US8029782 Therapeutic ribonucleases
10/04/2011	US8029774 Wound healing polymeric networks
10/04/2011	US8029772 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
10/04/2011	US8029770 Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
10/04/2011	US8029768 pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
10/04/2011	US8029561 Drug combination useful for prevention of restenosis
10/04/2011	US8029542 Supplemental spine fixation device and method
10/04/2011	CA2673462C Solid oral dosage forms of valsartan
10/04/2011	CA2669481C Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
10/04/2011	CA2642508C Method of removal of hyperplastic skin lesions
10/04/2011	CA2620274C Methods for the treatment of senile dementia of the alzheimer's type
10/04/2011	CA2615917C Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
10/04/2011	CA2589059C Trace elements
10/04/2011	CA2532755C Veterinary aqueous injectable suspensions containing florfenicol
10/04/2011	CA2519350C Composition comprising particulate zinc materials having a defined crystallite size
10/04/2011	CA2507505C N-arylsulfonyl-3-aminoalkoxyindoles
10/04/2011	CA2494536C A 12-membered ring macrolide active substance
10/04/2011	CA2491079C Therapeutic piperazine derivatives useful for treating pain
10/04/2011	CA2488915C Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
10/04/2011	CA2481770C Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis
10/04/2011	CA2480308C Antisense iap nucleobase oligomers and uses thereof
10/04/2011	CA2467828C Pharmaceutical formulations comprising an immune response modifier
10/04/2011	CA2453837C Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
10/04/2011	CA2452871C Oxymorphone controlled release formulations
10/04/2011	CA2447417C Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
10/04/2011	CA2438520C Phthalazinone-piperidino-derivatives as pde4 inhibitors
10/04/2011	CA2434773C Piperazinylcarbonylquinolines and -isoquinolines
10/04/2011	CA2426031C 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
10/04/2011	CA2394117C Process for the preparation of arylethanolamine derivatives having anti-obesity and anti-diabetic properties
10/04/2011	CA2391898C Compositions and medical devices utilizing bioabsorbable polymeric waxes
10/04/2011	CA2371839C Hydroxymatairesinol in cancer prevention
10/04/2011	CA2346330C Medicated chewing gum delivery system for nicotine
10/04/2011	CA2340103C Carbohydrate mixtures
10/04/2011	CA2245702C Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same
10/04/2011	CA2224075C Vectors for the diagnosis and treatment of solid tumors including melanoma
10/04/2011	CA2087884C Vitaletheine and use in cell culture and therapy
10/03/2011	WO2011027806A1 Therapeutic agent for anxiety disorders
10/03/2011	CA2772922A1 Therapeutic agent for anxiety disorders
10/03/2011	CA2772920A1 Therapeutic agent for mood disorders
09/2011
09/29/2011	WO2011120053A1 Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
09/29/2011	WO2011120049A1 Methods for enhancing nucleic acid hybridization
09/29/2011	WO2011120044A1 Conjugated neuroactive steroid compositions and methods of use
09/29/2011	WO2011120040A2 Thrombin inhibiting compositions
09/29/2011	WO2011120025A1 Indazolyl-pyrimidines as kinase inhibitors
09/29/2011	WO2011120023A1 Nucleic acid compounds for inhibiting survivin gene expression uses thereof
09/29/2011	WO2011119995A2 Formulations and methods of use
09/29/2011	WO2011119988A1 Methods of treatment of hepatocellular carcinoma
09/29/2011	WO2011119984A1 Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
09/29/2011	WO2011119969A1 Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
09/29/2011	WO2011119929A2 Composition for enhancing athletic performance
09/29/2011	WO2011119919A1 Adenosine compounds and their use thereof
09/29/2011	WO2011119887A1 Rna interference in dermal and fibrotic indications
09/29/2011	WO2011119871A1 Rna interference in ocular indications
09/29/2011	WO2011119866A1 Compositions and methods for glucose transport inhibition
09/29/2011	WO2011119863A1 Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
09/29/2011	WO2011119853A1 Analogues for the treatment or prevention of flavivirus infections
09/29/2011	WO2011119852A1 Reduced size self-delivering rnai compounds
09/29/2011	WO2011119848A1 Compositions and methods for prevention and treatment of wounds
09/29/2011	WO2011119842A1 Compositions and methods for treating neurological disorders
09/29/2011	WO2011119798A1 Methods for reducing superoxide anions in eukaryotic organisms
09/29/2011	WO2011119777A2 Compositions and methods for treatment of neurodegenerative disease
09/29/2011	WO2011119759A1 Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
09/29/2011	WO2011119748A1 Compositions comprising a prosamide for treating hair loss, hair thinning, hair color loss
09/29/2011	WO2011119738A2 Methods of treatment using stem cell mobilizers
09/29/2011	WO2011119732A2 Method for integrin ligand discovery
09/29/2011	WO2011119722A2 Use of anatabine to treat inflammation and methods of synthesizing anatabine
09/29/2011	WO2011119704A1 Trpv4 antagonists
09/29/2011	WO2011119701A1 Trpv4 antagonists
09/29/2011	WO2011119698A1 Polymorphic forms st-246 and methods of preparation
09/29/2011	WO2011119694A1 Trpv4 antagonists
09/29/2011	WO2011119693A1 Trpv4 antagonists
09/29/2011	WO2011119674A1 Methods and compositions related to modified adenosines for controlling off-target effects in rna interference
09/29/2011	WO2011119663A1 Chemical compounds
09/29/2011	WO2011119649A2 Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
09/29/2011	WO2011119622A1 DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1α,25- DIHYDROXYVITAMIN D3
09/29/2011	WO2011119610A2 (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
09/29/2011	WO2011119588A1 Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
09/29/2011	WO2011119585A2 Aerosol foams comprising clindamycin phosphate
09/29/2011	WO2011119566A1 Process for preparing carbamoylpyridone derivatives and intermediates
09/29/2011	WO2011119565A1 Imaging agents for detecting neurological disorders
09/29/2011	WO2011119559A1 Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
09/29/2011	WO2011119549A1 Trioxacarcins and uses thereof
09/29/2011	WO2011119544A1 Sarms and method of use thereof
09/29/2011	WO2011119518A1 Soluble guanylate cyclase activators
09/29/2011	WO2011119517A2 Antimicrobial compositions
09/29/2011	WO2011119477A2 Pharmaceutical compositions of carvedilol salts and process for preparation thereof
09/29/2011	WO2011119465A1 Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
09/29/2011	WO2011119461A1 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
09/29/2011	WO2011119345A2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
09/29/2011	WO2011119290A1 Emulsions useful in beverages
09/29/2011	WO2011119288A2 Multilayer melt-extruded film
09/29/2011	WO2011119282A1 Molecular crystal of (4 -(1,8-naphthyridin-2-yl) piperidin - 1 -yl ) pyrimidine derivative
09/29/2011	WO2011119247A2 Topical skincare composition
09/29/2011	WO2011119194A1 Compositions and methods for non-toxic delivery of antiprogestins
09/29/2011	WO2011119136A1 Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases
09/29/2011	WO2011119126A1 Use of oxalic acid in the production of a therapeutic preparation with anti-tumour activity in relation to malignant cells, a therapeutic preparation based thereon and a method of treatment
09/29/2011	WO2011119125A1 Use of lithium oxalate in production of a therapeutic preparation with anti-tumour activity in relation to malignant cells, a therapeutic preparation based thereon and a method of treatment
09/29/2011	WO2011119049A1 Carvacrol and/or thymol or composition thereof for preventing of infection infestation of an ectoparasitic copepod in fish
09/29/2011	WO2011119047A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia

1 ... 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 ... 7860